Promotheus Laboratories launches ProOnc cancer diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Firm debuts Oct. 15 three new cancer diagnostics based on microRNA technology. ProOnc TumorSource is designed to identify tissue of origin in metastatic tumors; among the 25 tissue types it can identify are cancers of the colon, liver, brain, breast, kidney, lung, ovary, pancreas, prostate and testis, Promotheus says. ProOnc Squamous measures the expression level of a squamous microRNA biomarker to differentiate patients with and without lung cancer. ProOnc Mesothelioma differentiates malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura, the firm says. The home brews are run at a CLIA-certified lab, the company notes
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.